Last 3,243
Change Today 0.00 / 0.00%
Volume 0.0
As of 10:24 AM 09/1/14 All times are local (Market data is delayed by at least 15 minutes).

compugen ltd (CGEN) Snapshot

Open
$3,178
Previous Close
$3,243
Day High
$3,252
Day Low
$3,178
52 Week High
02/11/14 - $4,740
52 Week Low
05/19/14 - $2,631
Market Cap
1.6B
Average Volume 10 Days
34.8K
EPS TTM
$-0.98
Shares Outstanding
48.3M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for COMPUGEN LTD (CGEN)

compugen ltd (CGEN) Related Businessweek News

No Related Businessweek News Found

compugen ltd (CGEN) Details

Compugen Ltd., a therapeutic product discovery company, is engaged in the research, development, and commercialization of therapeutic and diagnostic biomarker product candidates primarily in the United States, Europe, and Israel. It focuses on the therapeutic proteins and monoclonal antibodies to address unmet needs in the fields of immunology and oncology. The company’s therapeutic proteins pipeline includes CGEN-15001, CGEN-15021, CGEN-15091, CGEN-15031, and CGEN-15051 fusion protein candidates for the treatment of autoimmune diseases and inflammatory conditions, such as multiple sclerosis and rheumatoid arthritis. Its monoclonal antibody therapy product candidates include CGEN-15001T, CGEN-15022, and CGEN-15049; and CGEN-671, a novel antibody-drug conjugate. Compugen Ltd. was incorporated in 1993 and is headquartered in Tel Aviv, Israel.

Founded in 1993

compugen ltd (CGEN) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

compugen ltd (CGEN) Key Developments

Compugen May Seek Acquisitions

Compugen Ltd. (NasdaqGM:CGEN) may seek acquisitions. Compugen has made a shelf registration for up to $200 million issue of securities. Net proceeds from the sale of securities will be used for operations and for other general corporate purposes, which may include repayment or refinancing of indebtedness or other corporate borrowings, working capital, intellectual property protection and enforcement, capital expenditures, investments, acquisitions or collaborations, research and development and product development.

Compugen Ltd. Appoints Ari Krashin as Chief Financial Officer, Effective as of September 9, 2014

Compugen Ltd. announced the appointment of Mr. Ari Krashin as Chief Financial Officer, effective as of September 9, 2014. Mr. Krashin will report to Dr. Anat Cohen Dayag, Compugen's President and Chief Executive Officer, and will have direct responsibility for all financial functions of the company, including investor relations, and in addition will oversee the legal function. Mr. Krashin previously served as Chief Financial Officer of Gilat Satellite Networks where he was responsible for the company's global finance and related operations, including M&A, business development, investor relations and administration.

Compugen Ltd. Announces Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2014; Provides Capital Expenditure Guidance for the Full Year of Fiscal 2014

Compugen Ltd. announced unaudited consolidated earnings results for the second quarter and six months ended June 30, 2014. For the quarter, the company announced revenues of $1,964,000 compared to $22,000 for the same period a year ago. Operating loss was $3,318,000 compared to $4,719,000 for the same period a year ago. Net loss before taxes was $2,259,000 compared to $3,039,000 for the same period a year ago. Net loss was $2,319,000 compared to $3,039,000 for the same period a year ago. Diluted net loss per ordinary share was $0.07 compared to $0.09 for the same period a year ago. These substantial increase in revenue from the prior year periods resulted primarily from a milestone payment and the recognizable portions of a non-refundable upfront payment in accordance with US GAAP revenue recognition accounting, in each case pursuant to the August 2013 collaboration and license agreement with Bayer Pharma AG. For the six months, the company announced revenues of $4,097,000 compared to $184,000 for the same period a year ago. Operating loss was $6,629,000 compared to $8,683,000 for the same period a year ago. Net loss before taxes was $4,157,000 compared to $6,413,000 for the same period a year ago. Net loss was $4,217,000 compared to $6,413,000 for the same period a year ago. Diluted net loss per ordinary share was $0.09 compared to $0.18 for the same period a year ago. The reductions in net loss for the second quarter and the first six months of 2014, compared with the comparable periods in 2013, were attributable to increases in revenues recognized for the quarter and the first six months, compared with the comparable periods in 2013, partially off-set by increased corporate expenses for such periods, primarily relating to research and development. The company provided capital expenditure guidance for the full year of fiscal 2014. The company announced that with respect to calendar year 2014, the company has budgeted total cash expenditures (without taking into consideration actual to date or potential additional cash receipts) of approximately $24 million.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
CGEN:IT 3,243.00 0.00

CGEN Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for CGEN.
View Industry Companies
 

Industry Analysis

CGEN

Industry Average

Valuation CGEN Industry Range
No financial data is available for CGEN.
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact COMPUGEN LTD, please visit www.cgen.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.